Open AccessPersistence and Discontinuation of Oral Anticoagulant: Remaining Issues Not Addressed by Phase III Clinical Trials
Author(s) -
Ayabe Kengo,
Goto Shinichi,
Goto Shinya
Publication year - 2016
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.116.003258
Subject(s) - medicine , discontinuation , warfarin , atrial fibrillation , stroke (engine) , anticoagulant drug , clinical trial , intensive care medicine , clinical practice , anticoagulant , family medicine , mechanical engineering , engineering
There is general consensus that oral anticoagulant (OAC) therapy is recommended for stroke prevention in patients with atrial fibrillation (AF) and stroke risk factors.[1][1], [2][2], [3][3] It is important to note that approximately one fourth of patients with AF who initiated OAC therapy (vitamin